Overview

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures

Status:
RECRUITING
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label extension (OLE) phase.
Phase:
PHASE2
Details
Lead Sponsor:
Biohaven Therapeutics Ltd.